The invention itself consists of a patch on which are mounted very sensitive microphones that measure differences in turbulence in the coronary artery. The sound is transferred to an electronic system that is able to process the audio files and quickly come up with a so-called Coronary Artery Disease (CAD) score for whether the patient should be referred for further examination or treatment.
Today, there are no equivalent simple models that can give the doctor a basis for predicting whether the patient is at risk of getting a blood clot. This means that many patients are referred to a hospital for expensive medical examinations even though deposits in the blood vessels are not the problem. When a cardiac patch is an affordable and accurate method, it will be used by the practitioners, who can then determine whether the patient should undergo a more comprehensive medical examination. In the long run, therefore, the invention can save both lives and money by ensuring that the right people are referred for examination.
Besides Coloplast and Aalborg University, the Department of Cardiology at Copenhagen University Hospital (Rigshospitalet) is also a participant in the project behind the company, which also receives support from the Danish National Advanced Technology Foundation.
Since its inception, the company has been through two further funding rounds, during which Acarix raised 33 million (2010) and 27 million (2013) respectively from the company's existing shareholders, Sunstone Capital, Seed Capital, Coloplast and Seventure.
- Acarix's website
- Read article from MedWatch.dk: Medical company raises DKK 27 million from investors (in Danish)
- Read article from The Engineer (Ingeniøren): New electronics company set to discover the risk of blood clot in three minutes (in Danish)
- Read article from The Engineer (Ingeniøren): Advanced sound measurement reveals potentially lethal heart disease (in Danish)